Evidence map›Paper›PMID 33917843›Full record

ReviewBiomolecules2021

Neuroprotective Herbs for the Management of Alzheimer's Disease.

Julie Gregory, Yasaswi V Vengalasetti, Dale E Bredesen, Rammohan V Rao

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05594329 (A Randomized Controlled Trial to Investigate the Neurological, Inflammatory and Metabolic Effects of Acute Mushroom Intervention in Older Adults), which is not on this map. Cited by 87 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05594329 nacompletednot on this mapstarted 2022, after this paper: background citation

A Randomized Controlled Trial to Investigate the Neurological, Inflammatory and Metabolic Effects of Acute Mushroom Intervention in Older Adults (OYSACO)

TypeinterventionalSponsorUniversity of ReadingRan2022 to 2022Enrolled33ConditionsCognitive Change, Mood, Metabolism, Inflammatory ResponseArmsInstant noodle soup containing containing the equivalent of 2 servings (18.78g) of powdered Pleurotus oyster mushroom., Instant noodle soup containing containing the equivalent of 1 serving (9.39g) of powdered Pleurotus oyster mushroom., Instant noodle soup containing containing the equivalent of 0.5 serving (4.70g) of powdered Pleurotus oyster mushroom., Control instant noodle soup
3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Neurological Effects ofNutrients · 2026
    Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Subcutaneous application ofFrontiers in public health · 2026
    Observational
  17. Review
  18. Review
  19. Review
  20. Article

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Julie GregoryApollo Health, P.O. Box 117040, Burlingame, CA 94011, USA.
Yasaswi V VengalasettiCollege of Medicine, University of Central Florida, Orlando, FL 32827, USA.
Dale E BredesenApollo Health, P.O. Box 117040, Burlingame, CA 94011, USA.
Rammohan V RaoApollo Health, P.O. Box 117040, Burlingame, CA 94011, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background-Alzheimer's disease (AD) is a multifactorial, progressive, neurodegenerative disease that is characterized by memory loss, personality changes, and a decline in cognitive function. While the exact cause of AD is still unclear, recent studies point to lifestyle, diet, environmental, and genetic factors as contributors to disease progression. The pharmaceutical approaches developed to date do not alter disease progression. More than two hundred promising drug candidates have failed clinical trials in the past decade, suggesting that the disease and its causes may be highly complex. Medicinal plants and herbal remedies are now gaining more interest as complementary and alternative interventions and are a valuable source for developing drug candidates for AD. Indeed, several scientific studies have described the use of various medicinal plants and their principal phytochemicals for the treatment of AD. This article reviews a subset of herbs for their anti-inflammatory, antioxidant, and cognitive-enhancing effects. Methods-This article systematically reviews recent studies that have investigated the role of neuroprotective herbs and their bioactive compounds for dementia associated with Alzheimer's disease and pre-Alzheimer's disease. PubMed Central, Scopus, and Google Scholar databases of articles were collected, and abstracts were reviewed for relevance to the subject matter. Conclusions-Medicinal plants have great potential as part of an overall program in the prevention and treatment of cognitive decline associated with AD. It is hoped that these medicinal plants can be used in drug discovery programs for identifying safe and efficacious small molecules for AD.

Indexed as

AcorusAlzheimer DiseaseCentellaCentral Nervous SystemGinkgo bilobaHumansPhytochemicalsPlant ExtractsPlants, MedicinalAshwagandhaPhytochemicalsPlant ExtractsAlzheimer’s diseaseashwagandhabrahmicat’s clawginkgo bilobagotu kolaherbslion’s maneneurodegenerationsaffronshankhpushpitriphalaturmeric

Identifiers

PMID33917843
PMCPMC8068256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.